Figure 1: A computed tomography angiography (CTA) study performed for transcatheter aortic valve replacement planning.  Interventional imagers created and interpret these images as part of the heart team.
Feature | Structural Heart | Nadeen N. Faza, M.D., Dee Dee Wang, M.D., Joao Cavalcante, M.D., Andrew D. Choi, M.D., Jeffrey B. Geske, M.D., and Stephen H. Little, M.D.

Recent months have signaled a new and exciting era in the dynamic world of structural heart disease (SHD). The COAPT ...

Home April 24, 2019
Home
Technology | Drug-Eluting Balloons

Orchestra BioMed Inc. has secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its Virtue Sirolimus-Eluting Balloon for the treatment of coronary in-stent restenosis (ISR).

Home April 24, 2019
Home
Boston Scientific Receives FDA Approval for Lotus Edge Aortic Valve System
Feature | Heart Valve Technology | Dave Fornell, Editor

Boston Scientific Corp. announced it has received U.S. Food and Drug Administration (FDA) approval for the Lotus Edge Aortic Valve System. Delivered via a minimally invasive procedure, this transcatheter aortic valve replacement (TAVR) technology is approved for patients with severe aortic stenosis who are considered at high risk for surgical valve replacement via open heart surgery.

Home April 23, 2019
Home
News | Cath Lab

Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may help predict who will be readmitted to the hospital within a month, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

Home April 23, 2019
Home
News | Heart Valve Technology

April 22, 2019 — Five cardiovascular professional societies released a new consensus document on optimizing care for ...

Home April 22, 2019
Home
News | Cardiovascular Business

The Medicare Hospital Insurance (HI) Trust Fund, which funds Medicare Part A, will only be able to pay full benefits for Medicare beneficiaries until 2026, according to the 2019 annual report from the Medicare Board of Trustees. The Supplementary Medical Insurance (SMI) Trust Fund, which funds Medicare Part B and D, is expected to be adequately financed in all years, but the aging population and rising healthcare costs are projected to grow SMI costs from 2.1 percent of gross domestic product (GDP) in 2018 to approximately 3.7 percent of GDP in 2038.

Home April 22, 2019
Home
News | Congenital Heart

New guidelines that classified more children as having elevated blood pressure are better at predicting which kids are likely to develop heart disease when they reach adulthood, according to new research in the American Heart Association’s journal Hypertension. The guidelines were issued by the American Academy of Pediatrics (AAP) in 2017 and endorsed by the American Heart Association.

Home April 22, 2019
Home
News | Stem Cell Therapies

Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal of Cardiothoracic Surgery1. The prospective, single-arm study included 1,420 patients in 42 hospitals across the United States and represents the largest pericardial-closure study conducted to date. The goal of the study was to evaluate clinical outcomes with pericardial reconstruction using ProxiCor, the company’s proprietary decellularized extracellular matrix (ECM) scaffold designed for the repair of the pericardium.

Home April 19, 2019
Home
News | Electronic Medical Records (EMR)

The U.S. Department of Health and Human Services (HHS) is extending the public comment period by 30 days for two proposed regulations aimed at promoting the interoperability of health information technology (health IT) and enabling patients to electronically access their health information. The new deadline for the submission of comments – June 3, 2019 – will allow additional time for the public to review the proposed regulations.

Home April 19, 2019
Home
News | Heart Failure

Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic drug empagliflozin can treat and reverse the progression of heart failure in non-diabetic animal models. Their study also shows that this drug can make the heart produce more energy and function more efficiently. The results were published in the April 23 issue of the Journal of the American College of Cardiology.

Home April 19, 2019
Home
News | Antiplatelet and Anticoagulation Therapies

A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse cardiovascular event by almost 50 percent, if they adhere to taking a statin medication as prescribed by their doctors.

Home April 18, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

Biotronik announced the European market release of what it calls the world’s smallest implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices that are approved for 3T full-body magnetic resonance imaging (MRI) scans.

Home April 18, 2019
Home
News | Cath Lab

April 18, 2019 — The U.S. Food and Drug Administration published a draft guidance titled, “Technical Considerations for ...

Home April 18, 2019
Home
Sponsored Content | Videos | Information Technology

With Intellispace Enterprise Edition as the foundation, Philips Healthcare is connecting facilities and service areas ...

Home April 17, 2019
Home
Videos | Artificial Intelligence

Paul Chang, M.D., professor of radiology, vice chair of radiology informatics and medical director for enterprise ...

Home April 17, 2019
Home
Subscribe Now